MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A

Katsuya Ohta, Hiromitsu Hoshino, Jinhua Wang, Shigeshi Ono, Yuuki Iida, Keisuke Hata, Sharon K. Huang, Steven D Colquhoun, Dave S.B. Hoon

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n=47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumorsuppressor genes PTEN and CDKN1A, respectively, and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.

Original languageEnglish (US)
Pages (from-to)3211-3224
Number of pages14
JournalOncotarget
Volume6
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

MicroRNAs
Phosphatidylinositol 3-Kinases
Hepatocellular Carcinoma
Cell Movement
Cell Proliferation
Proto-Oncogene Proteins c-met
Apoptosis
Hepatocyte Growth Factor
3' Untranslated Regions
Neoplasms
Cell Line
Polymerase Chain Reaction

Keywords

  • Drug-sensitivity
  • Hepatocellular carcinoma
  • miR-93
  • Sorafenib and tivantinib

ASJC Scopus subject areas

  • Oncology

Cite this

MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. / Ohta, Katsuya; Hoshino, Hiromitsu; Wang, Jinhua; Ono, Shigeshi; Iida, Yuuki; Hata, Keisuke; Huang, Sharon K.; Colquhoun, Steven D; Hoon, Dave S.B.

In: Oncotarget, Vol. 6, No. 5, 01.01.2015, p. 3211-3224.

Research output: Contribution to journalArticle

Ohta, Katsuya ; Hoshino, Hiromitsu ; Wang, Jinhua ; Ono, Shigeshi ; Iida, Yuuki ; Hata, Keisuke ; Huang, Sharon K. ; Colquhoun, Steven D ; Hoon, Dave S.B. / MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. In: Oncotarget. 2015 ; Vol. 6, No. 5. pp. 3211-3224.
@article{0fe0545da1b24bde91b82cf83a615c73,
title = "MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A",
abstract = "To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n=47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumorsuppressor genes PTEN and CDKN1A, respectively, and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.",
keywords = "Drug-sensitivity, Hepatocellular carcinoma, miR-93, Sorafenib and tivantinib",
author = "Katsuya Ohta and Hiromitsu Hoshino and Jinhua Wang and Shigeshi Ono and Yuuki Iida and Keisuke Hata and Huang, {Sharon K.} and Colquhoun, {Steven D} and Hoon, {Dave S.B.}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3085",
language = "English (US)",
volume = "6",
pages = "3211--3224",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A

AU - Ohta, Katsuya

AU - Hoshino, Hiromitsu

AU - Wang, Jinhua

AU - Ono, Shigeshi

AU - Iida, Yuuki

AU - Hata, Keisuke

AU - Huang, Sharon K.

AU - Colquhoun, Steven D

AU - Hoon, Dave S.B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n=47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumorsuppressor genes PTEN and CDKN1A, respectively, and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.

AB - To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n=47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumorsuppressor genes PTEN and CDKN1A, respectively, and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.

KW - Drug-sensitivity

KW - Hepatocellular carcinoma

KW - miR-93

KW - Sorafenib and tivantinib

UR - http://www.scopus.com/inward/record.url?scp=84923274132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923274132&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3085

DO - 10.18632/oncotarget.3085

M3 - Article

VL - 6

SP - 3211

EP - 3224

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -